PTHS Company Profile and Key Details

Pelthos Therapeutics Inc. has 648.50 thousand shares outstanding. The public float is 616.46 thousand shares, elevated short interest at 0.83% of float. This equals 4.79 thousand shares. The short ratio is 0.03 days. Institutional investors hold 29.13% of the float. Insiders own 64.2%. Over the past six months, insider transactions show balanced activity. They sold 2.00 thousand shares across 1 transactions.

Pelthos Therapeutics Inc. generated EPS of -$18.46 over the past year. Five-year average earnings growth is -87.88%. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $50.00. The high target offers 134.1% upside. The low target suggests 95.08% downside. The mean target is $54.80. This offers 113.81% upside. Pelthos Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 691.04%. The prior quarter beat by 73.55%. Over the last six quarters, Apple has recorded several small beats. These include 73.55% in August 13, 2025.

Pelthos Therapeutics Inc. (NYSE:PTHS) closed at $26.76 USD, gaining $1.13 (4.41%) from the previous close of $25.63. The stock is currently mid-range between its 52-week high and low $5.90 and $54.29. With a market capitalization of about $17.35 million, Pelthos Therapeutics Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~4.12). Key stats such as the average daily volume over the past year has been around 21.77 thousand shares, volume is running light vs its 52-week average. Headquartered in Durham, NC, Pelthos Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Scott Plesha, the company employs approximately 4 people and listed since July 02, 2025. Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.

Short-term trend indicators are mixed aligned (SMA20 1.14%, SMA50 -12.51%, SMA200 21.14%). The stock’s 14-day RSI is 47.26 (neutral), while the ATR of 2.89 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -52.79% below its high and over 356.05% above its low. Average 10-day trading volume of 26.79 thousand shares is slightly above the 3-month average of 21.62 thousand, indicating heightened recent market interest.

Pelthos Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.85. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Pelthos Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -16.43%, with price expected at $21.42 by January 02, 2026, within a range of $19.31 to $23.67 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by March 19, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected gain of 75.26%, with price at $44.92 by December 18, 2026, within a range of $44.37 to $45.42.

currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Pelthos Therapeutics Inc. trading at a premium to the broader market with a P/E of -3.29. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $54.80, suggesting 113.81% upside. Our AI forecast model points to short-term weakness (-16.43% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term gain (75.26% over one year), with expected trading ranges indicating moderate volatility.

Pelthos Therapeutics Inc. trades at a P/E ratio of -3.29, slightly below the S&P 500 average, with a price-to-sales ratio of 2.22 and a price-to-book ratio of 1.33 suggesting the stock is closer to book value. The P/FCF stands at -0.97, also below market averages.